美国华人网FuninUSA_唐人社区_北美华人论坛:找礼品卡,找折扣,找报价,找工作,找内推,找项目,找股票

 找回密码
 立即注册
  • 澳洲传说中“巨猫”被目击:通体黑色
  • 2米长巨型响尾蛇与喵星人放一起后:竟相安无事
  • 珠峰大本营终于淘汰发电机:全部接入国家电网
  • 再也不怕堵了!史上最帅汽车:可垂直起飞
  • 日本天空惊现巨型十字架 网友:EVA来了!
  • 美国黄石公园美丽白狼神秘重伤:忍痛安乐死
  • 时速2000km!中国世界首条海底超级高铁呼之欲出
  • 飞鸟钻入引擎:美国国宝级轰炸机烧成灰烬
  • 图中竟然藏了一条蛇:网友找疯了
  • 科学家发现毛毛虫可完美降解塑料袋:效率极高
  • 特朗普的狂想——不切实际的公司税计划
  • 在Buffalo Wild Wings季度财报中出现了“天文误差”
  • Tom Lee警示下行风险,揭示市场三大“地雷”
  • 好消息!纳斯达克指数首破6000点,道指和纳指涨势喜人
  • 好消息!纳斯达克指数首破6000点,道指和纳指涨势喜人
  • AMD:增长和损失同在,有改变才会有进步
  • 巴菲特该高兴了,IBM加息至每股1.5美元
  • 法国大选是否能点燃美国市场?
  • 100天了,特朗普的“三驾马车”还能走多远
  • 对于石油,投资者难得保持一致意见:看跌
Logo1-800-PetMeds Free Shipping $49Take $10 Off Your First Order w/code: SAVE10 - 234 x 60
ASICS AmericaPagoda Piercing Banner 234x60Sierra Trading Post
搜索
查看: 3039|回复: 4

谈股论金 -(ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N- 唐人社区| ...

[复制链接]

23

主题

106

帖子

155

积分

注册会员

Rank: 2

积分
155
QQ
发表于 2016-9-7 15:21:00 | 显示全部楼层 |阅读模式
分享到:
{$content}

唐人社区-北美华人论坛-外贸论坛-谈股论金版-(ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N


  Stock
标 题: (ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is NO)


Is Mylan Labs (MYL) Stock a Bargain?
September 5, 2016
Salem, Massachusetts
By Timothy Lutts

The ongoing saga of Mylan’s EpiPen has enough plot points to make a major
motion picture.

On one side are the innocent victims, who rely on the EpiPen to protect
themselves from anaphylaxis, typically from foods (particularly nuts) or
insect stings.

On the other side are Mylan Labs, the FDA, insurance companies, lobbyists
and legislators, who have created a situation where people in the U.S. are
being asked to pay more than $600 for a pair of EpiPens that each deliver
roughly $1 worth of adrenalin.

In the meantime, people in Europe enjoy a very competitive market where they
can choose from as many as eight alternative—and cheaper—products!

Yes, all these parties in the U.S. are “just doing their jobs” and many
are sincerely “trying to help.” But the net effect of their actions has
brought us to this place where a company with $10 billion in sales—and a
near-monopoly on a life-saving medical device—is paying its CEO, the
daughter of a U.S. Senator, $19 million a year—while regular people beg,
borrow and steal to afford the company’s product.

Something is wrong. Very wrong!

But before I get into the details, let me step back—as I like to do—and
look at the big picture, time-wise. In this case, this approach is
particularly relevant because Mylan Labs (MYL) was the first stock I ever
bought.

That was back in December 1984, when generic drugs were just gaining
traction and little Mylan Labs made six of the most widely prescribed
generic drugs: ampicillin, penicillin V.K., penicillin G., tetracycline,
erythromycin and furosemide.

The company’s sales that year were just $37 million, which shows you how
small the generic drug business was!

But the company was growing fast. My father, Carlton Lutts, had just
recommended the stock in Cabot Market Letter—since renamed Cabot Growth
Investor. And I liked the story of the little company that was beating the
big guys with cheaper generics.

The next year, Mylan received approval for seven more generic drugs: Aldomet
, Dalmane, Darvocet-N, Inderal, Motrin, Norpace and Valium. Business was hot!

But the following year, I sold all the stocks I owned to help build my first
house—which I still live in, though it’s grown substantially larger.

But what if I had kept some Mylan? How would that have worked out?

Well, if I had kept, say, $1,000 in the stock, it would have grown to $32,
846 today. That’s a compound annual return of 11.5%—good but not great.

More important, my fast-growing little stock stopped being a market-beater
in 1992. For all the company’s growth, MYL over the past 24 years has done
no better than the broad market.

Furthermore—and more relevant to the EpiPen discussion—the stock’s
biggest gains in that 24-year period came from 2009 through 2015, smack in
the middle of the period when Mylan raised the price of a two-pack of
EpiPens from $100 to more than $600!

The price hikes goosed revenues; the revenues goosed earnings; and the
earnings goosed the stock price.

The Power of Lobbyists

But it wasn’t just price hikes that greased the skids for Mylan. Thanks to
an army of paid lobbyists, Mylan was able to:

Get Sanofi's competing product recalled in November 2015.

Get Teva's generic device rejected by the FDA in March 2016, thanks in part
to a “citizens petition” that was filed by Mylan.

Get the FDA to broaden the indications for its EpiPen to include risk of
anaphylaxis.

Get Congress to generate legislation making EpiPens available in public
places in the same way that defibrillators are.

Get the "School Access to Emergency Epinephrine Act" passed. The act not
only protects anyone from liability if they administer epinephrine to a
child in a school, it also provides financial incentives for schools that
didn’t already stock EpiPens to start stocking them.

Get people to increasingly ignore the fact that antihistamines and steroids
can often be used as substitutes for epinephrine, in the process
conditioning all of us to believe that the firm’s products are the only
real solution. In fact, the word EpiPen is fast becoming as generic as
previous brand names Kleenex, Scotch Tape and Velcro.

And acquire Abbott Labs of Ireland, thus lowering its tax rate from 35% to
20%.

Lastly, there’s the little matter of the Heather Bresch’s college degree.

When she became Chief Operating Officer of Mylan in 2007—having worked her
way up from clerk—her resume showed an Executive Masters of Business
Administration degree from West Virginia University. But when the press
investigated, the school said she hadn’t earned the degree, and in fact had
completed only 26 of the 48 credit-hours required. However, the school soon
created some credits for her out of thin air (her father was governor at
the time) and officially granted her the degree. But the subterfuge soon
came to light, and in 2008, the school’s President, provost and business
school dean all resigned.

Four years later, Bresch became CEO of Mylan. (Think about that for a minute
!)

Now, everything Mylan has done at this point is perfectly legal—at least as
far as I can tell.

However, there’s no question that the firm has used its considerable
financial and political capital to influence public policy.

And while the shareholders of the company have clearly benefited, the costs
of the company’s success have been borne by all of us, who pay higher
prices for drugs because competitors are thwarted, pay higher prices for
insurance, and pay higher taxes because Mylan doesn’t pay its fare share.

And now Mylan has dipped into its bag of tricks once more to announce that
it will soon release a generic version of its own EpiPen, thus providing
some relief to consumers from its own price hikes. But skeptics—and their
numbers are growing rapidly—see this as simply one more crafty self-serving
move, first by calming the critical mob and second by getting a jump on
Teva, which may finally be allowed by the FDA to sell its generic
epinephrine injector next year.

So what do I recommend?

First, I think we need to rein in the influence of big business on politics.
The growing disenfranchisement of the American people is not healthy for a
purportedly democratic society. In fact, it’s a trend that could end badly.

Second, I think we need to pressure the FDA to loosen up a bit, to allow
more competition into the market. The perfect should not be the enemy of the
good.

Third, I think we need tort reform, so that “fear of being sued” isn’t
the driving force behind every decision.

And fourth, I recommend that you sell any Mylan (MYL) stock that you have.

Yes, Mylan is already down 46% from its high, so technically it is oversold.
Short-term, a bounce would not be surprising.

And yes, the company is expected to grow earnings 18% next year and trades
at a price/earnings ratio of only 9, so by this simple measure, the stock
looks like a bargain.

But looking at the big picture, I can’t call MYL a bargain today. On the
contrary, I think the company has just finished an uncharacteristically
strong eight-year run when it pulled all the tricks it could out of the hat.

I think slowing growth is in the company’s future.

And I think the combination of that slowing growth with the tarnished public
perception of the company thanks to the EpiPen price-gouging will sour
growing numbers of investors on the stock as the months go by.

The main trend in MYL is still down and I think it will trend longer than
most people anticipate.

Thus, I recommend you put your hard-earned money somewhere else.
--
【COACH美国代购总群】99634155
回复 百度谷歌雅虎搜狗搜搜有道360奇虎

举报

12

主题

221

帖子

239

积分

中级会员

Rank: 3Rank: 3

积分
239
QQ
发表于 2016-9-7 18:27:51 | 显示全部楼层
Stock
标  题: (ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is NO)


Is Mylan Labs (MYL) Stock a Bargain?
September 5, 2016
Salem, Massachusetts
By Timothy Lutts

The ongoing saga of Mylan’s EpiPen has enough plot points to make a major
motion picture.

On one side are the innocent victims, who rely on the EpiPen to protect
themselves from anaphylaxis, typically from foods (particularly nuts) or
insect stings.

On the other side are Mylan Labs, the FDA, insurance companies, lobbyists
and legislators, who have created a situation where people in the U.S. are
being asked to pay more than $600 for a pair of EpiPens that each deliver
roughly $1 worth of adrenalin.

In the meantime, people in Europe enjoy a very competitive market where they
can choose from as many as eight alternative—and cheaper—products!

Yes, all these parties in the U.S. are “just doing their jobs” and many
are sincerely “trying to help.” But the net effect of their actions has
brought us to this place where a company with $10 billion in sales—and a
near-monopoly on a life-saving medical device—is paying its CEO, the
daughter of a U.S. Senator, $19 million a year—while regular people beg,
borrow and steal to afford the company’s product.

Something is wrong. Very wrong!

But before I get into the details, let me step back—as I like to do—and
look at the big picture, time-wise. In this case, this approach is
particularly relevant because Mylan Labs (MYL) was the first stock I ever
bought.

That was back in December 1984, when generic drugs were just gaining
traction and little Mylan Labs made six of the most widely prescribed
generic drugs: ampicillin, penicillin V.K., penicillin G., tetracycline,
erythromycin and furosemide.

The company’s sales that year were just $37 million, which shows you how
small the generic drug business was!

But the company was growing fast. My father, Carlton Lutts, had just
recommended the stock in Cabot Market Letter—since renamed Cabot Growth
Investor. And I liked the story of the little company that was beating the
big guys with cheaper generics.

The next year, Mylan received approval for seven more generic drugs: Aldomet
, Dalmane, Darvocet-N, Inderal, Motrin, Norpace and Valium. Business was hot!

But the following year, I sold all the stocks I owned to help build my first
house—which I still live in, though it’s grown substantially larger.

But what if I had kept some Mylan? How would that have worked out?

Well, if I had kept, say, $1,000 in the stock, it would have grown to $32,
846 today. That’s a compound annual return of 11.5%—good but not great.

More important, my fast-growing little stock stopped being a market-beater
in 1992. For all the company’s growth, MYL over the past 24 years has done
no better than the broad market.

Furthermore—and more relevant to the EpiPen discussion—the stock’s
biggest gains in that 24-year period came from 2009 through 2015, smack in
the middle of the period when Mylan raised the price of a two-pack of
EpiPens from $100 to more than $600!

The price hikes goosed revenues; the revenues goosed earnings; and the
earnings goosed the stock price.

The Power of Lobbyists

But it wasn’t just price hikes that greased the skids for Mylan. Thanks to
an army of paid lobbyists, Mylan was able to:

Get Sanofi's competing product recalled in November 2015.

Get Teva's generic device rejected by the FDA in March 2016, thanks in part
to a “citizens petition” that was filed by Mylan.

Get the FDA to broaden the indications for its EpiPen to include risk of
anaphylaxis.

Get Congress to generate legislation making EpiPens available in public
places in the same way that defibrillators are.

Get the "School Access to Emergency Epinephrine Act" passed. The act not
only protects anyone from liability if they administer epinephrine to a
child in a school, it also provides financial incentives for schools that
didn’t already stock EpiPens to start stocking them.

Get people to increasingly ignore the fact that antihistamines and steroids
can often be used as substitutes for epinephrine, in the process
conditioning all of us to believe that the firm’s products are the only
real solution. In fact, the word EpiPen is fast becoming as generic as
previous brand names Kleenex, Scotch Tape and Velcro.

And acquire Abbott Labs of Ireland, thus lowering its tax rate from 35% to
20%.

Lastly, there’s the little matter of the Heather Bresch’s college degree.

When she became Chief Operating Officer of Mylan in 2007—having worked her
way up from clerk—her resume showed an Executive Masters of Business
Administration degree from West Virginia University. But when the press
investigated, the school said she hadn’t earned the degree, and in fact had
completed only 26 of the 48 credit-hours required. However, the school soon
created some credits for her out of thin air (her father was governor at
the time) and officially granted her the degree. But the subterfuge soon
came to light, and in 2008, the school’s President, provost and business
school dean all resigned.

Four years later, Bresch became CEO of Mylan. (Think about that for a minute
!)

Now, everything Mylan has done at this point is perfectly legal—at least as
far as I can tell.

However, there’s no question that the firm has used its considerable
financial and political capital to influence public policy.

And while the shareholders of the company have clearly benefited, the costs
of the company’s success have been borne by all of us, who pay higher
prices for drugs because competitors are thwarted, pay higher prices for
insurance, and pay higher taxes because Mylan doesn’t pay its fare share.

And now Mylan has dipped into its bag of tricks once more to announce that
it will soon release a generic version of its own EpiPen, thus providing
some relief to consumers from its own price hikes. But skeptics—and their
numbers are growing rapidly—see this as simply one more crafty self-serving
move, first by calming the critical mob and second by getting a jump on
Teva, which may finally be allowed by the FDA to sell its generic
epinephrine injector next year.

So what do I recommend?

First, I think we need to rein in the influence of big business on politics.
The growing disenfranchisement of the American people is not healthy for a
purportedly democratic society. In fact, it’s a trend that could end badly.

Second, I think we need to pressure the FDA to loosen up a bit, to allow
more competition into the market. The perfect should not be the enemy of the
good.

Third, I think we need tort reform, so that “fear of being sued” isn’t
the driving force behind every decision.

And fourth, I recommend that you sell any Mylan (MYL) stock that you have.

Yes, Mylan is already down 46% from its high, so technically it is oversold.
Short-term, a bounce would not be surprising.

And yes, the company is expected to grow earnings 18% next year and trades
at a price/earnings ratio of only 9, so by this simple measure, the stock
looks like a bargain.

But looking at the big picture, I can’t call MYL a bargain today. On the
contrary, I think the company has just finished an uncharacteristically
strong eight-year run when it pulled all the tricks it could out of the hat.

I think slowing growth is in the company’s future.

And I think the combination of that slowing growth with the tarnished public
perception of the company thanks to the EpiPen price-gouging will sour
growing numbers of investors on the stock as the months go by.

The main trend in MYL is still down and I think it will trend longer than
most people anticipate.

Thus, I recommend you put your hard-earned money somewhere else.
--

24

主题

414

帖子

449

积分

中级会员

Rank: 3Rank: 3

积分
449
QQ
发表于 2016-9-8 02:44:06 | 显示全部楼层
Stock
标  题: Re: (ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N


don't catch falling knife.

【 在 waya (waya) 的大作中提到: 】
: Is Mylan Labs (MYL) Stock a Bargain?
: September 5, 2016
: Salem, Massachusetts
: By Timothy Lutts
: The ongoing saga of Mylan’s EpiPen has enough plot points to make a major
: motion picture.
: On one side are the innocent victims, who rely on the EpiPen to protect
: themselves from anaphylaxis, typically from foods (particularly nuts) or
: insect stings.
: On the other side are Mylan Labs, the FDA, insurance companies, lobbyists
: ...................



--

17

主题

228

帖子

261

积分

中级会员

Rank: 3Rank: 3

积分
261
QQ
发表于 2016-9-8 07:25:04 | 显示全部楼层
Stock
标  题: Re: (ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N


很危险的股票。不过除了Epipen其他提价不是很夸张。

当然了,这种股票大多数人不适合。
--

25

主题

1166

帖子

2298

积分

金牌会员

Rank: 6Rank: 6

积分
2298
QQ
发表于 2016-9-24 00:49:55 | 显示全部楼层
支持支持再支持
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

美国华人网|唐人社区|什么值得买FunInUSA.net发布的谈股论金 -(ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N- 唐人社区| ...帖子由网友提供或转载于网络,若发布的谈股论金 -(ZZ) Is Mylan Labs (MYL) Stock a Bargain? (His answer is N- 唐人社区| ...侵犯了您的权益,请联系我们.
Sasa.com

Copyright ©2011 FunInUSA.NET All Right Reserved.  Powered by Discuz! X3.0 小黑屋

本站信息均由会员发表,不代表美国华人网FunInUSA|唐人社区的立场,如侵犯了您的权利请发帖投诉  技术支持: 美国华人网FunInUSA|唐人社区

安全联盟认证 安全联盟认证

快速回复 返回顶部 返回列表